ORYZON to Initiate ESCAPE: a Phase II Clinical Trial to Test Efficacy of Vafidemstat in Severely ill COVID-19 Patients

NEXT STORY
Orion upgrades full-year outlook for 2020
PREV STORY
Aptose Biosciences Files Proxy Statement, Announces Online Only Annual General Meeting
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Rexahn Announces Presentations at the 2019 ASCO Genitourinary Cancers Symposium

ROCKVILLE, Md., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), ...

author_avatar
NASDAQ Market News

EyePoint Pharmaceuticals and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize Durasert™ Three-Year Treatment for Posterior Segment Uveitis in the Greater China Region

WATERTOWN, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty ...

author_avatar
NASDAQ Market News

Equillium to Present Data at the 2020 American College of Rheumatology Meeting Demonstrating CD6 Modulation Improves Kidney and Skin Pathology in Preclinical Models of Systemic Lupus Erythematosus

author_avatar
NASDAQ Market News